{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:32:49Z","timestamp":1792632769707,"version":"4.5.0"},"reference-count":227,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:p>Dry eye disease (DED) is a rapidly growing ocular surface disease with a significant socioeconomic impact that affects the patients\u2019 visual function and, thus, their quality of life. It is distinguished by a loss of tear film homeostasis, leading to tear film instability, hyperosmolarity, ocular surface inflammation, and neurosensory abnormalities, with all of these playing etiological roles in the propagation of the vicious DED circle. While current treatments primarily focus on reducing tear film instability and hyperosmolarity, increasingly more attention is being placed on tackling the underlying inflammation that propagates and potentiates these factors. As such, preclinical models are crucial to further elucidate the DED pathophysiology and develop novel therapeutic strategies. This review outlines the role of inflammation in DED, highlighting related signs and diagnostic tools before focusing on relevant preclinical animal models and potential therapeutic strategies to tackle DED-associated inflammation.<\/jats:p>","DOI":"10.1089\/jop.2024.0103","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:19:52Z","timestamp":1727914792000},"page":"638-658","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":19,"title":["Inflammation in Dry Eye Disease\u2014Pathogenesis, Preclinical Animal Models, and Treatments"],"prefix":"10.1177","volume":"40","author":[{"given":"Santosh","family":"Bhujbal","sequence":"first","affiliation":[{"name":"Buchanan Ocular Therapeutics Unit, Department of Ophthalmology, Aotearoa-New Zealand National Eye Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilva D.","family":"Rupenthal","sequence":"additional","affiliation":[{"name":"Buchanan Ocular Therapeutics Unit, Department of Ophthalmology, Aotearoa-New Zealand National Eye Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Steven","sequence":"additional","affiliation":[{"name":"Clinic I for Internal Medicine and Department of Ophthalmology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3831-3833","authenticated-orcid":false,"given":"Priyanka","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Buchanan Ocular Therapeutics Unit, Department of Ophthalmology, Aotearoa-New Zealand National Eye Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.02-0665"},{"key":"e_1_3_5_3_2","first-page":"113","article-title":"Molecular mechanism of ocular surface damage: Application to an in vitro dry eye model on human corneal epithelium","volume":"17","author":"Meloni M","year":"2011","unstructured":"Meloni M, , De Servi B, , Marasco D, et al. Molecular mechanism of ocular surface damage: Application to an in vitro dry eye model on human corneal epithelium. Mol Vis, 2011; 17:113\u2013126.","journal-title":"Mol Vis"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-1055"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.7.3950"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.008"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2015.0071"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-307415"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000240079.24583.a1"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000569"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00055735-200012000-00016"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2015.07.040"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13020207"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.004"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1542-0124(12)70081-2"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.04-0299"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.011"},{"key":"e_1_3_5_18_2","first-page":"S9","article-title":"Autoimmune epitheliitis: Sjogren\u2019s syndrome","volume":"12","author":"Skopouli FN","year":"1994","unstructured":"Skopouli FN, , Moutsopoulos HM. Autoimmune epitheliitis: Sjogren\u2019s syndrome. Clin Exp Rheumatol, 1994; 12 (Suppl 11):S9\u2013S11.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0501-3"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.4317\/jced.53605"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjopt.2016.02.001"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080874"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200406180-00020"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.12.1275"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1076\/ceyr.19.3.201.5309"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002299"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-2417-5_81"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9394(14)73983-2"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/754923"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.5935\/0004-2749.20180012"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.17.2114"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000227889.11500.6f"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003226-199605000-00001"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6997c"},{"key":"e_1_3_5_35_2","first-page":"1055","article-title":"Androgen regulation of gene expression in human meibomian gland and conjunctival epithelial cells","volume":"18","author":"Khandelwal P","year":"2012","unstructured":"Khandelwal P, , Liu S, , Sullivan DA. Androgen regulation of gene expression in human meibomian gland and conjunctival epithelial cells. Mol Vis, 2012; 18:1055\u20131067.","journal-title":"Mol Vis"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.12.7072"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003226-200308000-00006"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-0717-8_56"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTO.S84795"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1350-9462(97)00001-3"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.2105\/ajph.23.9.935"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200312000-00008"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.82.1.39"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-19757"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.001"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1177\/112067210301300201"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2019.01.004"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4557-2876-3.00007-9"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-82753-9.00002-3"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.3126\/nepjoph.v14i2.38928"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e31803dcda2"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.826530"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.15-17433"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000000600"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2015.103"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.04.020"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.07.028"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3182541e9a"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1097\/ico.0000000000000175"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2013.561"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-014-0006-y"},{"key":"e_1_3_5_62_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13167-016-0065-3"},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310866"},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8751"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201344081"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1110611"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e318033a729"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep357"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029017"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2019.1594933"},{"key":"e_1_3_5_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2016.12.008"},{"key":"e_1_3_5_72_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-10516"},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1542-0124(12)70222-7"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1006\/exer.1998.0570"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1159\/000131097"},{"key":"e_1_3_5_76_2","doi-asserted-by":"publisher","DOI":"10.1006\/exer.2000.0855"},{"issue":"2","key":"e_1_3_5_77_2","first-page":"377","article-title":"Cyclosporine therapy suppresses ocular and lacrimal gland disease in MRL\/Mp-lpr\/lpr mice","volume":"37","author":"Jabs DA","year":"1996","unstructured":"Jabs DA, , Lee B, , Burek CL, et al. Cyclosporine therapy suppresses ocular and lacrimal gland disease in MRL\/Mp-lpr\/lpr mice. Invest Ophthalmol Vis Sci, 1996; 37(2):377\u2013383.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_5_78_2","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.081058"},{"key":"e_1_3_5_79_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-19159"},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2017.272"},{"key":"e_1_3_5_81_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2005.21.139"},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2021.108538"},{"key":"e_1_3_5_83_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0959-9673.2006.00456.x"},{"key":"e_1_3_5_84_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-007-0548-y"},{"key":"e_1_3_5_85_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.19-27843"},{"key":"e_1_3_5_86_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.279"},{"key":"e_1_3_5_87_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126191"},{"key":"e_1_3_5_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2023.09.006"},{"key":"e_1_3_5_89_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-0720"},{"key":"e_1_3_5_90_2","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7204951"},{"key":"e_1_3_5_91_2","first-page":"257","article-title":"A mouse dry eye model induced by topical administration of benzalkonium chloride","volume":"17","author":"Lin Z","year":"2011","unstructured":"Lin Z, , Liu X, , Zhou T, et al. A mouse dry eye model induced by topical administration of benzalkonium chloride. Mol Vis, 2011; 17:257\u2013264.","journal-title":"Mol Vis"},{"key":"e_1_3_5_92_2","doi-asserted-by":"publisher","DOI":"10.1111\/jfbc.14352"},{"key":"e_1_3_5_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2016.03.006"},{"key":"e_1_3_5_94_2","doi-asserted-by":"publisher","DOI":"10.3390\/nu11112792"},{"key":"e_1_3_5_95_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.2.246"},{"key":"e_1_3_5_96_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.05-0380"},{"key":"e_1_3_5_97_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2018.0044"},{"key":"e_1_3_5_98_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxins11020066"},{"key":"e_1_3_5_99_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.02-1319"},{"key":"e_1_3_5_100_2","doi-asserted-by":"publisher","DOI":"10.1097\/jcma.0000000000000529"},{"key":"e_1_3_5_101_2","doi-asserted-by":"publisher","DOI":"10.1159\/000055537"},{"key":"e_1_3_5_102_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-5224.2010.00834.x"},{"key":"e_1_3_5_103_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000085"},{"key":"e_1_3_5_104_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.04-1344"},{"key":"e_1_3_5_105_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-016-3572-y"},{"key":"e_1_3_5_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2014.05.001"},{"issue":"3","key":"e_1_3_5_107_2","first-page":"632","article-title":"A mouse model of keratoconjunctivitis sicca","volume":"43","author":"Dursun D","year":"2002","unstructured":"Dursun D, , Wang M, , Monroy D, et al. A mouse model of keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci, 2002; 43(3):632\u2013638.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_5_108_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.1995.11.503"},{"key":"e_1_3_5_109_2","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.10830"},{"key":"e_1_3_5_110_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2015.09.019"},{"key":"e_1_3_5_111_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003226-200405000-00015"},{"key":"e_1_3_5_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(89)32753-9"},{"key":"e_1_3_5_113_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910770"},{"key":"e_1_3_5_114_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003226-200301000-00007"},{"key":"e_1_3_5_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2018.05.004"},{"key":"e_1_3_5_116_2","doi-asserted-by":"publisher","DOI":"10.1186\/1746-1596-9-5"},{"key":"e_1_3_5_117_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0960-0760(99)00119-3"},{"key":"e_1_3_5_118_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-22071"},{"key":"e_1_3_5_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2005.04.019"},{"key":"e_1_3_5_120_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2009.09.009"},{"key":"e_1_3_5_121_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(79)90052-7"},{"key":"e_1_3_5_122_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003226-199811000-00014"},{"key":"e_1_3_5_123_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.159"},{"key":"e_1_3_5_124_2","first-page":"257","article-title":"A mouse dry eye model induced by topical administration of benzalkonium chloride","volume":"17","author":"Lin Z","year":"2011","unstructured":"Lin Z, , Liu X, , Zhou T, et al. A mouse dry eye model induced by topical administration of benzalkonium chloride. Molecular Vision, 2011; 17:257\u2013264.","journal-title":"Molecular Vision"},{"key":"e_1_3_5_125_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8553"},{"key":"e_1_3_5_126_2","doi-asserted-by":"publisher","DOI":"10.1159\/000519458"},{"key":"e_1_3_5_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2022.109127"},{"key":"e_1_3_5_128_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2016.11.016"},{"key":"e_1_3_5_129_2","first-page":"2222","article-title":"Lacrimal gland inflammatory cytokine gene expression in the botulinum toxin B-induced murine dry eye model","volume":"13","author":"Park CY","year":"2007","unstructured":"Park CY, , Zhuang W, , Lekhanont K, et al. Lacrimal gland inflammatory cytokine gene expression in the botulinum toxin B-induced murine dry eye model. Mol Vis, 2007; 13:2222\u20132232.","journal-title":"Mol Vis"},{"key":"e_1_3_5_130_2","first-page":"1803","article-title":"Topical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model","volume":"18","author":"Zhu L","year":"2012","unstructured":"Zhu L, , Zhang C, , Chuck RS. Topical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model. Mol Vis, 2012; 18:1803\u20131812.","journal-title":"Mol Vis"},{"key":"e_1_3_5_131_2","first-page":"250","article-title":"Inflammatory cytokine expression on the ocular surface in the Botulium toxin B induced murine dry eye model","volume":"15","author":"Zhu L","year":"2009","unstructured":"Zhu L, , Shen J, , Zhang C, et al. Inflammatory cytokine expression on the ocular surface in the Botulium toxin B induced murine dry eye model. Mol Vis, 2009; 15:250\u2013258.","journal-title":"Mol Vis"},{"key":"e_1_3_5_132_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2006.0071"},{"key":"e_1_3_5_133_2","doi-asserted-by":"publisher","DOI":"10.1097\/IIO.0000000000000169"},{"key":"e_1_3_5_134_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000133994.22392.47"},{"key":"e_1_3_5_135_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4280"},{"key":"e_1_3_5_136_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2556-5"},{"issue":"2","key":"e_1_3_5_137_2","first-page":"119","article-title":"Lifitegrast ophthalmic solution 5% (Xiidra) for dry eye disease","volume":"98","author":"Patel J","year":"2018","unstructured":"Patel J, , Franko J. Lifitegrast ophthalmic solution 5% (Xiidra) for dry eye disease. Am Fam Physician, 2018; 98(2):119\u2013120.","journal-title":"Am Fam Physician"},{"key":"e_1_3_5_138_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.006"},{"key":"e_1_3_5_139_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2022.0133"},{"key":"e_1_3_5_140_2","doi-asserted-by":"publisher","DOI":"10.2147\/opth.s1409"},{"key":"e_1_3_5_141_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)90171-9"},{"key":"e_1_3_5_142_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.04.052"},{"key":"e_1_3_5_143_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2019-315747"},{"key":"e_1_3_5_144_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S323301"},{"key":"e_1_3_5_145_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2020.0014"},{"key":"e_1_3_5_146_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2017.1341988"},{"key":"e_1_3_5_147_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S279051"},{"key":"e_1_3_5_148_2","doi-asserted-by":"publisher","DOI":"10.4137\/OED.S16067"},{"key":"e_1_3_5_149_2","doi-asserted-by":"publisher","DOI":"10.2478\/s11658-008-0041-6"},{"key":"e_1_3_5_150_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2017.03.006"},{"key":"e_1_3_5_151_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2016.04.002"},{"key":"e_1_3_5_152_2","doi-asserted-by":"publisher","DOI":"10.4155\/cli.14.135"},{"key":"e_1_3_5_153_2","unstructured":"National Library of Medicine (NLM) a National Institutes of Health (NIH) institute. Available from: https:\/\/dailymed.nlm.nih.gov\/"},{"key":"e_1_3_5_154_2","unstructured":"Restasis (cyclosporine ophthalmic emulsion) [package insert]. Restasis (cyclosporine ophthalmic emulsion) [package insert]. Allergan: Irvine CA; 2017."},{"key":"e_1_3_5_155_2","unstructured":"Compendium em. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/6937\/smpc#gref"},{"key":"e_1_3_5_156_2","volume-title":"Sun Pharma Global FZE; 2019","year":"2019","unstructured":"CEQUA\u2122 (cyclosporine ophthalmic solution) 0.09% [Package insert]. In: Sun Pharma Global FZE; 2019. US Food and Drug Administration: 2019."},{"key":"e_1_3_5_157_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2019.02.010"},{"key":"e_1_3_5_158_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002633"},{"key":"e_1_3_5_159_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S228070"},{"key":"e_1_3_5_160_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2018.01.019"},{"key":"e_1_3_5_161_2","unstructured":"CyclASol for the treatment of signs and symptoms of Dry Eye Disease (DED). Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03292809"},{"key":"e_1_3_5_162_2","unstructured":"US Food and Drug Administration. VEVYE (cyclosporine ophthalmic solution) 0.1% [Package insert]. Novaliq GmbH: Heidelberg Germany; 2023."},{"key":"e_1_3_5_163_2","doi-asserted-by":"publisher","DOI":"10.1177\/2515841419870366"},{"key":"e_1_3_5_164_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S126668"},{"key":"e_1_3_5_165_2","unstructured":"XIIDRA\u00ae (lifitegrast ophthalmic solution) [Package insert]. Novartis Pharmaceuticals Corporation US Food and Drug Administration; 2020."},{"key":"e_1_3_5_166_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.09.025"},{"key":"e_1_3_5_167_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.11.003"},{"key":"e_1_3_5_168_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.08.001"},{"key":"e_1_3_5_169_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.38.1.97"},{"key":"e_1_3_5_170_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjopt.2013.12.003"},{"key":"e_1_3_5_171_2","unstructured":"Board HUMR. Anti-Inflammatory Drops For Chronic Dry Eye. Philadelphia USA; 2021. Available from: https:\/\/chronicdryeye.net\/anti-inflammatory-drops [Last Accessed; 07\/11\/2023]."},{"key":"e_1_3_5_172_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3181a06c31"},{"key":"e_1_3_5_173_2","first-page":"205","article-title":"Corneal melts associated with topically applied nonsteroidal anti-inflammatory drugs","volume":"99","author":"Flach AJ","year":"2001","unstructured":"Flach AJ. Corneal melts associated with topically applied nonsteroidal anti-inflammatory drugs. Trans Am Ophthalmol Soc, 2001; 99:205\u2013210. discussion 210-212","journal-title":"Trans Am Ophthalmol Soc"},{"key":"e_1_3_5_174_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e31824988e5"},{"key":"e_1_3_5_175_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2006.22.150"},{"key":"e_1_3_5_176_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_1244_17"},{"key":"e_1_3_5_177_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-0876-2"},{"key":"e_1_3_5_178_2","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.40360"},{"key":"e_1_3_5_179_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6997g"},{"key":"e_1_3_5_180_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4992"},{"key":"e_1_3_5_181_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3181cda38f"},{"key":"e_1_3_5_182_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3181ca38a0"},{"key":"e_1_3_5_183_2","doi-asserted-by":"publisher","DOI":"10.1590\/s0004-27492012000300006"},{"key":"e_1_3_5_184_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1444-0938.2010.00540.x"},{"key":"e_1_3_5_185_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-008-0096-9"},{"key":"e_1_3_5_186_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9394(00)00755-8"},{"key":"e_1_3_5_187_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2006.02.004"},{"key":"e_1_3_5_188_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071398"},{"key":"e_1_3_5_189_2","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2014.28.2.115"},{"key":"e_1_3_5_190_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X132640"},{"key":"e_1_3_5_191_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0054"},{"key":"e_1_3_5_192_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-004-1040-6"},{"key":"e_1_3_5_193_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.09.023"},{"key":"e_1_3_5_194_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2003.027573"},{"key":"e_1_3_5_195_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2009.03.015"},{"key":"e_1_3_5_196_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-011-1676-y"},{"key":"e_1_3_5_197_2","first-page":"317","article-title":"Therapeutic efficacy of trehalose eye drops for treatment of murine dry eye induced by an intelligently controlled environmental system","volume":"18","author":"Li J","year":"2012","unstructured":"Li J, , Roubeix C, , Wang Y, et al. Therapeutic efficacy of trehalose eye drops for treatment of murine dry eye induced by an intelligently controlled environmental system. Mol Vis, 2012; 18:317\u2013329.","journal-title":"Mol Vis"},{"key":"e_1_3_5_198_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2017.09.013"},{"key":"e_1_3_5_199_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S256351"},{"key":"e_1_3_5_200_2","doi-asserted-by":"publisher","DOI":"10.2147\/opth.S70623"},{"key":"e_1_3_5_201_2","doi-asserted-by":"publisher","DOI":"10.2147\/opth.S13773"},{"key":"e_1_3_5_202_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2012.05.003"},{"key":"e_1_3_5_203_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000788"},{"key":"e_1_3_5_204_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2009.12.007"},{"key":"e_1_3_5_205_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-813715"},{"key":"e_1_3_5_206_2","volume-title":"StatPearls","author":"Najem O","year":"2022","unstructured":"Najem O, , Shah MM, , De Jesus O. Serum osmolality. In: StatPearls. StatPearls: Treasure Island, FL; 2022."},{"key":"e_1_3_5_207_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009327.pub2"},{"key":"e_1_3_5_208_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000971908.98421.2d"},{"issue":"5","key":"e_1_3_5_209_2","first-page":"515","article-title":"Serum and in vitro production of IL-1 receptor antagonist correlate with C-reactive protein levels in newly diagnosed, untreated lupus patients","volume":"19","author":"Liou LB","year":"2001","unstructured":"Liou LB. Serum and in vitro production of IL-1 receptor antagonist correlate with C-reactive protein levels in newly diagnosed, untreated lupus patients. Clin Exp Rheumatol, 2001; 19(5):515\u2013523.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_5_210_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.01.034"},{"key":"e_1_3_5_211_2","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2015.1016180"},{"key":"e_1_3_5_212_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2011.01072.x"},{"key":"e_1_3_5_213_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-004-1106-5"},{"key":"e_1_3_5_214_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S327691"},{"key":"e_1_3_5_215_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2020.0087"},{"key":"e_1_3_5_216_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.01.011"},{"key":"e_1_3_5_217_2","unstructured":"Aldeyra\u2019s reproxalap fails to meet primary goal in dry eye disease trial. 2021. Available from: https:\/\/www.clinicaltrialsarena.com\/news\/aldeyra-reproxalap-primary-goal-trial\/?cf-view [Last accessed: November6 2021]."},{"key":"e_1_3_5_218_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2013.10.063"},{"key":"e_1_3_5_219_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0273-6"},{"key":"e_1_3_5_220_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0274-5"},{"key":"e_1_3_5_221_2","unstructured":"Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04206020"},{"key":"e_1_3_5_222_2","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2021.2011858"},{"issue":"9","key":"e_1_3_5_223_2","article-title":"Silk-Derived Protein-4 (SDP-4) inhibits nuclear factor Kappa B (NF-kappa B) inflammatory signaling that underlies Dry Eye Disease (DED)","volume":"60","author":"Infanger DW","year":"2019","unstructured":"Infanger DW, , Abdel-Naby W, , Kalal JJ, et al. Silk-Derived Protein-4 (SDP-4) inhibits nuclear factor Kappa B (NF-kappa B) inflammatory signaling that underlies Dry Eye Disease (DED). Invest Ophthalmol Vis Sci, 2019; 60(9).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_5_224_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-022-02245-1"},{"key":"e_1_3_5_225_2","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2018.1461909"},{"key":"e_1_3_5_226_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2269090"},{"key":"e_1_3_5_227_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000414"},{"issue":"12","key":"e_1_3_5_228_2","first-page":"2874","article-title":"A Phase 3 Multi-Center, Randomized Controlled Evaluation of the Efficacy, Safety and Tolerability of Isunakinra in Subjects with Moderate to Severe Dry Eye Disease Karen L","volume":"57","author":"Tubridy KL","year":"2016","unstructured":"Tubridy KL, , Goldstein MH, , Magill M. A Phase 3 Multi-Center, Randomized Controlled Evaluation of the Efficacy, Safety and Tolerability of Isunakinra in Subjects with Moderate to Severe Dry Eye Disease Karen L. Invest Ophthalmol Vis Sci, 2016; 57(12):2874\u20132874. Tubridy, PharmD 1 Michael H. Goldstein, MD, 1,2 Marianne Magill, MS 1 1 Eleven Biotherapeutics (Cambridge, MA) 2 New England Eye Center, Tuft\u2019s Medical Center (Boston, MA).","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2024.0103","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2024.0103","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2024.0103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:46:37Z","timestamp":1777646797000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2024.0103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":227,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,12,1]]}},"alternative-id":["10.1089\/jop.2024.0103"],"URL":"https:\/\/doi.org\/10.1089\/jop.2024.0103","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}